Vericel Corp. (NASDAQ:VCEL) shares shot up 6% during trading on Friday . The company traded as high as $2.43 and last traded at $2.28, with a volume of 280,052 shares changing hands. The stock had previously closed at $2.15.

Several research analysts recently issued reports on VCEL shares. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 target price on shares of Vericel Corp. in a research report on Tuesday, April 5th. Bank of America Corp. lowered Vericel Corp. from a “buy” rating to a “neutral” rating in a research report on Tuesday, April 5th.

The stock has a 50-day moving average of $2.22 and a 200 day moving average of $2.77. The company’s market capitalization is $51.17 million.

Vericel Corp. (NASDAQ:VCEL) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.17. The business earned $14.10 million during the quarter, compared to analysts’ expectations of $11.60 million. On average, equities research analysts anticipate that Vericel Corp. will post ($0.79) earnings per share for the current year.

Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.